Clinical evaluation of albendazole in the therapy of human trichinellosis
Kociecka, W.; Stefaniak, J.; Kacprzak, E.; Pakuła, M.
Wiadomosci Parazytologiczne 35(5): 457-466
1989
ISSN/ISBN: 0043-5163 PMID: 2815768 Document Number: 346266
Albendazole (Smith, Kline and French) was used to treat 25 trichinellosis patients. The drug was administered over a 6-day period, at a dose of 800 mg per day. Fifteen of the patients, who exhibited only s slight, asymptomatic course of trichinellosis, were treated with albendazole alone, while the remaining 10 patients, who exhibited a moderately severe course, were given a combination of albendazole and prednisoline in a combined dose of 105-240 mg. In the case of 2 patients, administration of the albendazole on the 6th and 7th days following infection prevented the appearance of clinical symptoms of the disease. Pathological symptoms were observed to abate between the 3rd and 9th days after the initiation of therapy in virtually all the subjects. Albendazole was well tolerated. None of the patients reported adverse reactions to albendazole therapy. Albenazole was found to be a valuable antihelminthic and can be recommended for the treatment of trichinellosis.